John McGee, Ph.D.

Scientific Co-Founder and Executive Vice President, Head of Platform

John McGee brings to Parabilis Medicines more than 15 years of experience in developing and applying new discovery and optimization technologies for helically constrained (Helicon) peptide therapeutics.

Prior to joining Parabilis Medicines, John was a postdoctoral research fellow at Harvard University, where he worked in the laboratory of Dr. Greg Verdine. At Harvard, he performed foundational work on both the de novo screening and multiplexing platforms that now form the core of Parabilis Medicines’ discovery engine.

John holds a B.S. in chemistry from Stanford University, where he worked in the laboratory of Dr. Eric Kool, and a Ph.D. in biochemistry from Harvard University, where he studied with Dr. Greg Verdine.